Back to briefingCommon Ground

World

Trump’s FDA nominee Overton faces committee vote next week with key Republicans uncommitted

The Food and Drug Administration is set to finish its safety review of the abortion pill mifepristone in March, but it may not have a permanent leader to oversee it. The agency has been without a permanent commissioner since Dr. Marty Makary resigned in May.

Dr. Heidi Overton, President Donald Trump’s pick to run the agency, faces a vote next week before the Health, Education, Labor and Pensions Committee. Key Republicans whose support she needs remain uncommitted, and with 11 votes needed in the 21-member committee, she can’t afford to lose a single Republican if all Democrats oppose her.

Democrats take power in the Senate on Jan. 3 after winning control in the midterm elections. According to a former congressional aide, if Overton isn’t confirmed by then, her nomination would most likely be returned to the White House, and Trump would have to nominate her again before a Democratic-controlled Senate, where her chances would be slim.

The senators could still be won over before the committee vote next Wednesday, and the White House has given no indication that it plans to withdraw her nomination.

Compare how each perspective frames this story

Sources 1